The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Dana E. Rathkopf
Consulting or Advisory Role - Janssen Oncology
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Mansoor N. Saleh
Honoraria - Genentech
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
 
Frank Yung-Chin Tsai
Research Funding - Tricon Pharmaceuticals (Inst)
 
Lee S. Rosen
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst)
 
Bonne J. Adams
Employment - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
 
Lilian Liu
Employment - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
 
Charles P. Theuer
Employment - Tricon Pharmaceuticals
Leadership - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
 
James L. Freddo
Employment - Ignyta; Tricon Pharmaceuticals
Leadership - Ignyta
Stock and Other Ownership Interests - Abbvie; Achillion Pharmaceuticals; Alexion Pharmaceuticals; aTyr Pharma; Biocryst; Curis; Dyax; Gilead Sciences; Ignyta; ImmunoGen; Incyte; Lilly; Mirati Therapeutics; Pfizer; Seagen
Consulting or Advisory Role - Tricon Pharmaceuticals
 
Neeraj Agarwal
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)